Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With FLOT in Stage III Gastric Adenocarcinoma
NCT07257575Phase 2Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in gastric adenocarcinoma, sponsored by Guangdong Provincial People's Hospital. Started Jan 2025; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07257575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257575.